ADA

July 07, 2021

Diana Isaacs, PharmD, offers perspective on her top 5 CGM-related studies or presentations from the American Diabetes Association's 81st Scientific Sessions.

July 02, 2021

Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.

June 30, 2021

Our editorial staff has selected a shortlist of highlighted data and summary slides on their picks of the most important data to be released at the American Diabetes Association's 81st Annual Scientific Sessions.

June 29, 2021

Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.

June 29, 2021

While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.

June 29, 2021

Using banked samples from the CANVAS trial, investigators demonstrate the ability of KidneyIntelX to monitor therapeutic response to SGLT2 inhibitors and predict disease progression in patients with type 2 diabetes and chronic kidney disease.

June 28, 2021

Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.

June 28, 2021

Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.

June 28, 2021

Using the ADA's celebration of the 100-year anniversary of the discovery of insulin as a backdrop, resident Advisory Board member Adam Sturts, DO, reflects on the history, present, and future of insulin from the perspective of a provider and a patient with type 1 diabetes.

June 28, 2021

A pair of studies presented at ADA 2021 detail the effects of an investigational 2.0 mg dose of semaglutide compared to semaglutide 1.0 mg (Ozempic) on glycemic control and body weight in patients with type 2 diabetes in SUSTAIN FORTE.